octocenter-logo

Ocrevus: Guide for Patients with Hepatitis B

Ocrevus: Guide for Patients with Hepatitis B

Ocrevus, clinically recognized as Ocrelizumab, is primarily a therapeutic agent for managing multiple sclerosis (MS). It's registered in the category of drugs known as monoclonal antibodies, and is dispensed intravenously. The drug's mechanism of action is directed to specific immune cells, namely B cells, which have a contributing role in MS progression. Ocrevus depletes these B cells, lessening the inflammatory response in the central nervous system, thereby decelerating the disease's evolution. The use of this medication is sanctioned for both alternating bouts of MS as well as primarily progressive MS, extending its therapeutic potential to a broad spectrum of patients.

Hepatitis B and its Impact

Hepatitis B is a hepatotropic infection induced by the hepatitis B virus (HBV), presenting a significant global health challenge, with an estimated chronic prevalence in 257 million individuals. Hepatitis B harbors potential to incite both acute and chronic hepatic disorders, escalating to potentially severe complications such as cirrhosis and hepatocellular carcinoma. The infection bears significant consequences on an individual's health, eliciting fatigue, jaundice and eventually impairing quality of life. Moreover, hepatitis B boasts multiple transmission avenues, inclusive of blood transfusions, needle sharing, sexual interactions and maternal-infant transmission during childbirth. Therefore, it is crucial for individuals afflicted with hepatitis B to be cognizant of their health status, and exercise necessary precautions to prevent propagation and competently manage their condition.

Interactions between Ocrevus and Hepatitis B

Potential Risks and Complications

There's a potential danger that Ocrevus could reactivate hepatitis B infection, culminating in liver damage that may prove severe. Hence, for patients who have had hepatitis B, ongoing careful monitoring during Ocrevus treatment is fundamental. Additionally, another complication, albeit potential, is the interaction between Ocrevus and treatments used for hepatitis B. Ocrevus might adversely affect the efficacy of antivirals used to regulate hepatitis B, potentially causing reduced viral control and an escalated chance of liver complications. As such, Ocrevus should be prescribed with cautiousness to patients managing multiple sclerosis and hepatitis B simultaneously. A close teamwork between neurologists and hepatologists is of immense importance in managing potential risks and complications.

ocrevus and hepatitis b

Monitoring and Management

Undeniably, careful monitoring and management of the therapeutic process are paramount when treating patients with Hepatitis B using Ocrevus. It's critical to perform periodic liver function tests, including a check on liver enzymes and the Hepatitis B viral load, to evaluate the drug's impact on the virus. Effective management of both conditions is ensured by a well-coordinated effort from both the neurologist and hepatologist. Any significant deviations in liver function or the Hepatitis B viral load must lead to an adjustment in the treatment plan. The management approach might include diligent observation, modification of dosage, temporary interruption of treatment, or initiation of an antiviral therapy for Hepatitis B. Therefore, by carefully monitoring and managing the combined influence of Ocrevus and Hepatitis B, potential risks and complications can be minimized.

Vaccination Recommendations

In the context of using Ocrevus for patients with Hepatitis B, complying with vaccination recommendations is essential. It's encouraged that individuals who haven't contracted the virus should receive the Hepatitis B vaccination. This advice extends to patients already on, or intending to commence, Ocrevus treatment. Vaccination not only offers immunity against the virus but also decreases the risk of related complications. Before Ocrevus administration, it's crucial to ensure that patients' Hepatitis B vaccinations are up-to-date. Should a patient's vaccination series remain incomplete, it's sensible to complete it before Ocrevus treatment begins. Also, carrying out routine Hepatitis B marker tests prior to treatment is vital to identify those who might already be infected and thus need further attention. Furthermore, to detect any potential reactivation during Ocrevus therapy, continued observation of Hepatitis B serologic markers is fundamental. Thus, strictly following vaccination recommendations aids in lessening the risks related to Hepatitis B and warranting secure and effective Ocrevus utilization in patients.

Conclusion

To sum up, healthcare professionals must vigilantly consider the interplay between Ocrevus and Hepatitis B. While specific data may not be abundant on this interaction, the prominence of Hepatitis B is a significant factor in patients undergoing Ocrevus treatment due to associated risks and complications. Rigorous patient surveillance for indications of Hepatitis B reactivation and its prompt intervention is fundamental in order to avert further complications. Additionally, adherence to vaccination guidelines is pivotal in minimizing Hepatitis B infection risks in vulnerable individuals. Augmented research is required to gain a nuanced understanding of Ocrevus and Hepatitis B conjunction; however, current studies indicate the criticality of consistent monitoring and apt management in bolstering patient safety.

Bibliography

  1. Tan, M., Bhadoria, A. S., Cui, F., Tan, A., Van Holten, J., Easterbrook, P., ... & Hutin, Y. (2021). Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. The lancet Gastroenterology & hepatology, 6(2), 106-119. (https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30307-1/fulltext)

  2. Ji, D. Z., Pang, X. Y., Shen, D. T., Liu, S. N., Goyal, H., & Xu, H. G. (2022). Global prevalence of occult hepatitis B: A systematic review and meta‐analysis. Journal of Viral Hepatitis, 29(5), 317-329. (https://onlinelibrary.wiley.com/doi/abs/10.1111/jvh.13660)

  3. Biolato, M., Bianco, A., Lucchini, M., Gasbarrini, A., Mirabella, M., & Grieco, A. (2021). The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review. CNS drugs, 35(8), 861-880. (https://link.springer.com/article/10.1007/s40263-021-00842-9)

  4. İNANÇ, Y., & NAZİK, S. Status of Hepatitis B Virus Serological In Patients With Multipl Sclerosis Using Ocrelizumab. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi, 18(3), 51-54. (https://dergipark.org.tr/en/download/article-file/2582676)

  5. Buonomo, A. R., Viceconte, G., Calabrese, M., De Luca, G., Tomassini, V., Cavalla, P., ... & Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group. (2022). Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. Journal of Neurology, 269(6), 3301-3307. (https://link.springer.com/article/10.1007/s00415-022-11009-x)

  6. Meunier, L. & Larrey, D. (2023). Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility. International Journal of Molecular Sciences. (https://www.mdpi.com/1422-0067/24/1/852/pdf)

  7. Liu, Y. C., Hsu, C. M., Hsiao, S. Y., & Hsiao, H. H. (2021). Hepatitis B virus infection in patients receiving allogeneic hematopoietic stem cell transplantation. Journal of Personalized Medicine. (https://www.mdpi.com/2075-4426/11/11/1108)